Official Title Ontogenesis of Categorization; Linking development, mechanisms, and biology

Purpose

The purpose of this study is to investigate the early development of attention, learning, and memory during childhood. Participation in this study includes 4, 90-minute-long visits to the lab per year. During these visits, your child will play 2-3 fun, computerized games. These games are designed to assess various aspects of their cognitive ability. 

The duration of the study will last 4 years.

Could this study be right for you?

Eligibility Criteria: 

• African-American/Black children who are 4 years old 

Age Range

4 - 4

Official Title Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent

Purpose

The purpose of the study is to determine if the investigational study drug will rapidly reduce depression associated with thoughts of harming oneself when given in addition to standard antidepressant medication.

Your participation in this study will last for a minimum of 14 weeks and maximum of 58 weeks.

Could this study be right for you?

• Aged 18-65 years old
• Diagnosed with major depressive disorder (MDD) with a current major depressive episode
• Having current suicidal ideation with intent
• Already in the hospital or agree to be hospitalized voluntarily for the required period of time

Age Range

18 and up

Official Title A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression

Purpose

This study is being done to see if the study drug, called BI 1358894, compared to a drug called quetiapine, may help people with Major Depressive Disorder (MDD) who do not progress when taking an antidepressant medication alone. This study will help to gain information for providing better or new possible treatments for people in the future.

This study will take place over a period of 13 weeks and have about 8 visits to the study center and 2 that will be done by phone.

Could this study be right for you?

• Aged 18-65 years old
• Diagnosed with Major Depressive Disorder (MDD)
• Currently depressed
• Taking an antidepressant

Age Range

18 and up

Official Title Safety of REL-1017 for Major Depressive Disorder (RELIANCE-OLS)

Purpose

This is a 1-year open-label study to access the safety of REL-1017, a study medication, once daily as a workable treatment of Major Depressive Disorder. Study participants will continue to take their current antidepressant therapy in addition to the study drug for the duration of the treatment period.

This study will last 13 months and you will come to the study site at least 15 times over this period. This will include 1 final visit about 1 month after you stop taking the study drug.

Could this study be right for you?

• Aged 18-65 years old
• Diagnosed with Major Depressive Disorder (MDD)
• Currently depressed
• Taking or having taken between 1 and 3 antidepressants for the current episode of depression

Age Range

18 and up

Official Title Study to Assess the Efficacy and Safety of Adjunctive NBI-1065845 in Adults with Major Depressive Disorder (MDD) (SAVITRI)

Purpose

The purpose of this study is to evaluate the effectiveness and safety of NBI-1065845 compared with placebo. In addition to the study drug, participants will continue their normal antidepressant medications. The main goal of this study is to examine the improving symptoms of depression.

The duration of the study will last 14 weeks, including up to 4 weeks of screening, 8 weeks of study drug dosing, and a follow-up period of 2 weeks.

Could this study be right for you?

• Aged 18-65 years old
• Have a diagnosis of Major Depressive Disorder (MDD)
• Currently depressed
• Poor response to antidepressant treatment

Age Range

18 and up

Official Title Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD (TERPSIS)

Purpose

To evaluate the efficacy and safety of study drug NBI-1065846, used as adjunctive treatment to oral antidepressant medication(s), compared with a placebo when treating symptoms of anhedonia.

Could this study be right for you?

• Aged 18-65 years old
• Diagnosis of MDD
• Currently on stable dose of at least one antidepressant
• Experiencing anhedonia (low interest, decreased enjoyment)

Age Range

18 and up

Official Title A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER)

Purpose

The purpose of this study is to examine whether active VNS Therapy treatment is superior to a no stimulation control in producing a reduction in baseline depressive symptom severity, based on multiple depression scale assessment tools at 12 months from randomization.

The duration of the study will consist over a 5 year period. You will visit the study site approximately 23 times after your implant surgery.

Could this study be right for you?

• Aged 18 years or older
• Must be in a major depressive episode (MDD or bipolar disorder) for ≥ two years or have at least had four episodes of depression including the current episode
• Patients depressive illness meets a minimum criteria of four prior failed treatments of adequate dose and duration

Age Range

18 and up

Official Title A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants with Treatment-resistant Depression

Purpose

The purpose of this study is to see if esketamine nasal spray alone is effective as a medication to improve depressive symptoms in adults with treatment-resistant depression when compared with placebo nasal spray.

The duration of the study consists up to a maximum of 24 weeks.

Could this study be right for you?

• Aged 18 years or older
• Must have had no response (less than 25% improvement) to at least 2 oral antidepressant treatments in the current episode of depression

Age Range

18 and up

Official Title Neural Mechanisms and Predictors of an Ultra-Brief Suicide Prevention Strategy

Purpose

This research study will look at how patterns of brain activity influence thoughts and behaviors. This research is being done to better explain why people have thoughts about suicide and how different suicide prevention strategies impact brain responses to emotional information.

Could this study be right for you?

Eligibility Criteria includes:

• 18-65 years old
• Generally medically and physically healthy
• Current suicidal ideation and intent OR no lifetime history of DSM-5 disorder, no lifetime suicidal intent or lifetime suicide attempts

(partial list of inclusion criteria)

Exclusion Criteria:

• Diagnosis of bipolar disorder, schizophrenia, mania, or psychosis
• Currently pregnant (positive pregnancy test), or trying to become pregnant (female)
• Presence of ferrous-containing metal in the body
• Inability to tolerate enclosed spaces

(partial list of exclusion criteria)

Age Range

18 and up

Official Title Neural Mechanisms of Mindfulness-based Cognitive Therapy (MBCT) for Posttraumatic Stress Disorder (PTSD) and COVID Pandemic-related Stress

Purpose

The purpose of this study is to better understand how Mindfulness-based Mind-Body therapies work to help people with Posttraumatic Stress and Stress and Anxiety related to the COVID Pandemic. We want to learn more about how these treatments work so we can put together better treatments for people with PTSD and stress or worry. Time in the study altogether is generally about 16-18 weeks

Could this study be right for you?

For those suffering from PTSD:

• Must be between 18 – 72 years of age
• Must have current clinically significant symptoms of PTSD
• Must be able to come to OSU Columbus campus for fMRI brain scan
• Must be appropriate for group therapy

Eligibility for those with Pandemic Stress:

• Must be between 18 – 72 years of age
• Must have current stress related to the pandemic
• Must reside in selected zip codes / under-resourced areas in central Ohio (areas with high levels of residents with incomes near the poverty line)
• Must be able to come to OSU Columbus campus for fMRI brain scan
• Must be appropriate for group therapy
• May have up to moderate depression and/or anxiety

Age Range

18 and up